Fenretinide in Healthy Young Women at Genetic and Familial Risk
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the effect of fenretinide (4-HPR), a vitamin A
derivative, in reducing the incidence of breast cancer in healthy premenopausal women at
increased familial/genetic risk for breast cancer